

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Joseph M. Penninger
Michael A. Crackower

Serial No.: 10/518,599

Filed: May 31, 2005

For: ACE2 ACTIVATION FOR TREATMENT
OF HEART, LUNG AND KIDNEY
DISEASE AND HYPERTENSION

Group Art Unit: 1632

Examiner: Anoop Kumar Singh

Atty. Dkt. No.: SONN:064US

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: August 8, 2008

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If the fee has been inadvertently omitted, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/SONN:064US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis Wohlers
Reg. No. 57,423
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 8, 2006

Form PTO-1449 (modified)		Atty. Docket No. SONN:064US	Serial No. 10/518,599
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Joseph M. Penninger Michael A. Crackower	
		Filing Date: May 31, 2005	Group: 1632
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C60	BLASTP 2.2.14 search for peptide DRVYIHPF Angiotensin II in all GenBank databases, May 7, 2006.
	C61	Imai <i>et al.</i> , "Angiotensin-converting enzyme 2 protects from severe acute lung failure," <i>Nature</i> , 436:112-116, 2005.
	C62	Kuba <i>et al.</i> , "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury," <i>Nature Medicine</i> , 11(8):875-879, 2005.
	C63	Macours <i>et al.</i> , "Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes," <i>International Review of Cytology</i> , 239:47-97.

25683602.1

EXAMINER:

DATE CONSIDERED:

EXAMINER. INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.